This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2004 Dec 9;351(24):2519-29.

doi: 10.1056/NEJMra041842.

Cancer of the ovary

Stephen A Cannistra¹

Affiliations

PMID: 15590954
DOI: 10.1056/NEJMra041842

Review

Cancer of the ovary

Stephen A Cannistra. N Engl J Med. 2004.

. 2004 Dec 9;351(24):2519-29.

doi: 10.1056/NEJMra041842.

Author

Stephen A Cannistra¹

Affiliation

¹ Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. scannist@bidmc.harvard.edu

PMID: 15590954
DOI: 10.1056/NEJMra041842

Erratum in

N Engl J Med. 2005 Jan 6;352(1):104

No abstract available

PubMed Disclaimer

Comment in

Cancer of the ovary.
Matulonis U, Abrahm JL. Matulonis U, et al. N Engl J Med. 2005 Mar 24;352(12):1268-9; author reply 1268-9. doi: 10.1056/NEJM200503243521222. N Engl J Med. 2005. PMID: 15788509 No abstract available.
Case 37-2004: postmenopausal bleeding and a cystic ovarian mass.
Price FV. Price FV. N Engl J Med. 2005 Mar 24;352(12):1269-70; author reply 1269-70. doi: 10.1056/NEJM200503243521223. N Engl J Med. 2005. PMID: 15788510 No abstract available.
Cancer of the ovary.
Liu CM. Liu CM. N Engl J Med. 2005 Mar 24;352(12):1268-9; author reply 1268-9. N Engl J Med. 2005. PMID: 15791705 No abstract available.

Similar articles

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME. Tan DS, et al. J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955455
Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Rabban JT, et al. Am J Surg Pathol. 2009 Aug;33(8):1125-36. doi: 10.1097/PAS.0b013e31819e986a. Am J Surg Pathol. 2009. PMID: 19440148
Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Hermsen BB, von Mensdorff-Pouilly S, Berkhof J, van Diest PJ, Gille JJ, Menko FH, Blankenstein MA, Kenemans P, Verheijen RH. Hermsen BB, et al. J Clin Oncol. 2007 Apr 10;25(11):1383-9. doi: 10.1200/JCO.2006.06.7884. J Clin Oncol. 2007. PMID: 17416858
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Carden CP, Yap TA, Kaye SB. Carden CP, et al. Curr Opin Oncol. 2010 Sep;22(5):473-80. doi: 10.1097/CCO.0b013e32833b5126. Curr Opin Oncol. 2010. PMID: 20485165 Review.
BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
Grenader T, Peretz T, Lifchitz M, Shavit L. Grenader T, et al. Breast. 2005 Aug;14(4):264-8. doi: 10.1016/j.breast.2005.01.005. Breast. 2005. PMID: 16085232 Review.

See all similar articles

Cited by

Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh MY, Horne D, Dellinger TH, Han ES, Jove R, Yim JH. Wen W, et al. Mol Cancer. 2015 May 1;14:100. doi: 10.1186/s12943-015-0366-5. Mol Cancer. 2015. PMID: 25928246 Free PMC article.
Biological characteristics of side population cells in a self-established human ovarian cancer cell line.
Wei Z, Lv S, Wang Y, Sun M, Chi G, Guo J, Song P, Fu X, Zhang S, Li Y. Wei Z, et al. Oncol Lett. 2016 Jul;12(1):41-48. doi: 10.3892/ol.2016.4565. Epub 2016 May 13. Oncol Lett. 2016. PMID: 27347097 Free PMC article.
Lack of prognostic relevance of Her-2/neu, topoisomerase IIα and EGFR in advanced ovarian carcinoma.
Engelstaedter V, Boda J, Völklein C, Engel J, Jeschke U, Kirchner T, Mayr D. Engelstaedter V, et al. Exp Ther Med. 2012 May;3(5):828-834. doi: 10.3892/etm.2012.481. Epub 2012 Feb 13. Exp Ther Med. 2012. PMID: 22969977 Free PMC article.
Ferroptosis of epithelial ovarian cancer: genetic determinants and therapeutic potential.
Lin CC, Chi JT. Lin CC, et al. Oncotarget. 2020 Sep 29;11(39):3562-3570. doi: 10.18632/oncotarget.27749. eCollection 2020 Sep 29. Oncotarget. 2020. PMID: 33062192 Free PMC article.
CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer.
Leung F, Soosaipillai A, Kulasingam V, Diamandis EP. Leung F, et al. Clin Biochem. 2012 Dec;45(18):1543-6. doi: 10.1016/j.clinbiochem.2012.08.011. Epub 2012 Aug 17. Clin Biochem. 2012. PMID: 22985796 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information